Newsroom

LONDON--(BUSINESS WIRE)--  Xtrackers Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-119.899 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 27 August 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, and to...

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in GoDaddy Inc. (NYSE: GDDY) that a securities class action is pending on behalf of purchasers of GDDY common stock between September 3, 2025 and February 24, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. GDDY closed at $92.30 on February 24, 2026 and at $79.12 the following session, a one-day loss of $13.18 per sha...

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Fractyl Health, Inc. (NASDAQ: GUTS) of a pending securities class action on behalf of shareholders who purchased securities between January 13, 2025 and January 29, 2026. Find out if you may be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.GUTS closed at a Class Period reference price of $1.83 on January 28, 2026, then fell $1.245 per share (68.03%) to $0....

LONDON--(BUSINESS WIRE)--  Xtrackers II Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-124.284 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 27 August 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, and...

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Joseph (JB) Long to join Northpointe Bancshares, as Chief Operating Officer and Chief Credit Officer...

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that a securities class action has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of shareholders who purchased securities between February 28, 2024 and February 25, 2026. Find out if you might qualify for recovery. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. PRCT shares declined more than 75% from a Class Period high of approximately $100.00 to less than $25.0...

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP notifies investors in Rackspace Technology, Inc. (NASDAQ: RXT) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between May 7, 2026 and July 8, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. RXT shares declined $2.21 per share, or 33.6%, on July 9, 2026, closing at $4.37 on unusually heavy volume. T...

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Taboola.com Ltd. (NASDAQ: TBLA) of a pending securities class action on behalf of shareholders who purchased securities between May 6, 2026 and August 4, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.TBLA shares fell $1.45, or 27.41%, to close at $3.84 on August 5, 2026, on unusually heavy trading volume, down from a Class Period h...

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP notifies institutional investors in Wix.com Ltd. (NASDAQ: WIX) that a class action has been filed on behalf of shareholders who purchased securities between February 19, 2025 and May 12, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.WIX declined from over $180 in late May 2025 to close at $55.32 on May 13, 2026 following a series of corrective dis...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The manuscript,...